Features of HCV recurrence in patients with HCV-related cirrhosis after liver transplantation and its antiviral and immunomodulatory therapies

• Main Author: JIAO Jian
• Format: Article
• Language: zho
• Published: Editorial Department of Journal of Clinical Hepatology 2014-01-01
• Series: Linchuang Gandanbing Zazhi
• Subjects: hepatitis viruses; liver cirrhosis; liver transplantation; hepatitis C; chronic; immunosuppressive agents
• Online Access: http://www.lcgdbzz.org/qk_content.asp?id=5652&ClassID=112814406

The best choice of treatment for patients with HCV-related cirrhosis may be liver transplantation once liver decompensation occurs. Immunoregulatory drugs, especially immunosuppressants, may be a main causative factor for accelerated HCV recurrence after liver transplantation. How to control HCV infection while reducing graft rejection is a meaningful problem that needs to be solved. The current antiviral and immunomodulatory therapies after HCV-related liver transplantation are summarized. Analysis showed that proper immunosuppression and antiviral therapy in patients with HCV-related cirrhosis after liver transplantation are of great significance for preventing HCV recurrence, prolonging graft survival, and improving prognosis. Sudden change in immunosuppressive therapy, such as rapid withdrawal or changing the dose or type of immunosuppressant, may lead to HCV recurrence. Slow progressive reduction in steroid hormone and maintenance treatment with azathioprine may be beneficial.